| Literature DB >> 27148195 |
Awa N'Diaye1, Lily Mijouin1, Mélanie Hillion1, Suraya Diaz2, Yoan Konto-Ghiorghi1, Giuseppe Percoco3, Sylvie Chevalier1, Luc Lefeuvre4, Nicholas J Harmer2, Olivier Lesouhaitier1, Marc G J Feuilloley1.
Abstract
Staphylococcus aureus and Staphylococcus epidermidis are two major skin associated bacteria, and Substance P (SP) is a major skin neuropeptide. Since bacteria are known to sense and response to many human hormones, we investigated the effects of SP on Staphylococci virulence in reconstructed human epidermis model and HaCaT keratinocytes. We show that SP is stimulating the virulence of S. aureus and S. epidermidis in a reconstructed human epidermis model. qRT-PCR array analysis of 64 genes expressed by keratinocytes in the response to bacterial infection revealed a potential link between the action of SP on Staphylococci and skin physiopathology. qRT-PCR and direct assay of cathelicidin and human β-defensin 2 secretion also provided that demonstration that the action of SP on bacteria is independent of antimicrobial peptide expression by keratinocytes. Considering an effect of SP on S. aureus and S. epidermidis, we observed that SP increases the adhesion potential of both bacteria on keratinocytes. However, SP modulates the virulence of S. aureus and S. epidermidis through different mechanisms. The response of S. aureus is associated with an increase in Staphylococcal Enterotoxin C2 (SEC2) production and a reduction of exolipase processing whereas in S. epidermidis the effect of SP appears mediated by a rise in biofilm formation activity. The Thermo unstable ribosomal Elongation factor Ef-Tu was identified as the SP-interacting protein in S. aureus and S. epidermidis. SP appears as an inter-kingdom communication factor involved in the regulation of bacterial virulence and essential for skin microflora homeostasis.Entities:
Keywords: biofilm; cathelicidin; human β-defensin 2; secretome; skin bacterial communication; substance P; thermo unstable ribosomal elongation factor
Year: 2016 PMID: 27148195 PMCID: PMC4832252 DOI: 10.3389/fmicb.2016.00506
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
List of the 64 genes encoding proteins investigated by qRT-PCR microarrays and mRNA expression calculated as percentage of control genes expression.
| Housekeeping proteins (References) | GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Control | Control |
| RPS28 | Ribosomal protein S28 | Control | Control | |
| RPL13A | Ribosomal protein L13a | Control | Control | |
| Antimicrobial peptides and innate immunity proteins | CAMP | Cathelicidin antimicrobial peptide | 152.1 | 41.4 |
| DEFB1 | Defensin, beta 1 | 167.1 | 52.2 | |
| DEFB103A | Defensin, beta 103A | ND | ND | |
| DEFB4A | Defensin, beta 4A | 199.5 | 11.9 | |
| PI3 | Peptidase inhibitor 3, skin-derived | 115.3 | 74.2 | |
| RNASE7 | Ribonuclease, RNase A family, 7 | 71.8 | 96.9 | |
| S100A7 | S100 calcium binding protein A7 | 154.7 | 31.2 | |
| HAMP | Hepcidin antimicrobial peptide | 317.2 | 65.8 | |
| TLR1 | Toll-like receptor 1 | 80.7 | 180.9 | |
| TLR2 | Toll-like receptor 2 | 100.1 | 174.2 | |
| TLR3 | Toll-like receptor 3 | 351.7 | 78.2 | |
| TLR4 | Toll-like receptor 4 | ND | ND | |
| S100A8 | S100 calcium binding protein A8 | 213.8 | 55.1 | |
| S100A9 | S100 calcium binding protein A9 | 90.5 | 107.2 | |
| Chemokines | IL8 | Interleukin 8 | 239.7 | 61.8 |
| CCL5 | Chemokine (C-C motif) ligand 5 | 223.1 | 101.9 | |
| CCL27 | Chemokine (C-C motif) ligand 27 | 129.4 | 69.9 | |
| CCL20 | Chemokine (C-C motif) ligand 20 | 167.9 | 8.9 | |
| CXCL1 | Chemokine (C-X-C motif) ligand 1 | 259.7 | 35.1 | |
| CXCL2 | Chemokine (C-X-C motif) ligand 2 | ND | ND | |
| CXCL6 | Chemokine (C-X-C motif) ligand 6 | ND | ND | |
| IL17C | Interleukin 17C | ND | ND | |
| CXCL3 | Chemokine (C-X-C motif) ligand 3 | ND | ND | |
| CXCL5 | Chemokine (C-X-C motif) ligand 5 | ND | ND | |
| CXCL10 | Chemokine (C-X-C motif) ligand 10 | 66.9 | 348.3 | |
| Cytokines and cytokines receptors | IL4R | Interleukin 4 receptor | 88.4 | 123.9 |
| IL13RA2 | Interleukin 13 receptor, alpha 2 | 174.2 | ND | |
| IL23A | Interleukin 23, alpha subunit p19 | ND | ND | |
| IL6 | Interleukin 6 | ND | ND | |
| TSLP | Thymic stromal lymphopoietin | 107.4 | 109.7 | |
| IL1A | Interleukin 1, alpha | 1088.6 | 62.1 | |
| IL1B | Interleukin 1, beta | 147.1 | 38.4 | |
| IL24 | Interleukin 24 | ND | ND | |
| TNF | Tumor necrosis factor | 82.2 | 215.1 | |
| Prostaglandin synthesis enzyme | PTGS2 | Prostaglandin-endoperoxide synthase 2 | 79.6 | 118 |
| Markers of differenciation and proliferation | FLG | Filaggrin | 156.5 | 61.1 |
| LOR | Loricrin | 150.6 | 77.7 | |
| CDSN | Corneodesmosin | 94.2 | 87.5 | |
| KRT5 | Keratin 5, type II | 32 | 393 | |
| KRT10 | Keratin 10 | 128.9 | 56 | |
| KRT19 | Keratin 19, type I | 115.3 | 95.9 | |
| MKI67 | Marker of proliferation Ki-67 | 106.2 | 174.5 | |
| Proteases and Metalloproteinases | ADAM17 | ADAM metallopeptidase domain 17 | 54.7 | 119.2 |
| KLK5 | Kallikrein-related peptidase 5 | 39.9 | 243.5 | |
| KLK7 | Kallikrein-related peptidase 7 | 141.4 | 65.5 | |
| MMP1 | Matrix metallopeptidase 1 | 215.6 | 211.4 | |
| MMP3 | Matrix metallopeptidase 3 | 322.8 | 51 | |
| MMP9 | Matrix metallopeptidase 9 | 68.6 | 530.2 | |
| Proteins involved in phagocytosis, invasion, and internalization | RAC1 | Ras-related C3 botulinum toxin substrate 1 | 162 | 71.9 |
| ILK | Integrin-linked kinase | 148 | 58.5 | |
| ITGA5 | Integrin alpha 5 | 245.1 | 420.5 | |
| ITGB1 | Integrin beta 1 | 114.9 | 102.03 | |
| DPP4 | Dipeptidyl-peptidase 4 | 121.6 | 228.7 | |
| STIP1 | Stress-induced phosphoprotein 1 | 57.6 | 154.4 | |
| Markers of cellular stress and apoptosis | ATF3 | Activating transcription factor 3 | 53.6 | 207.7 |
| HMOX1 | Heme oxygenase (decycling) 1 | 54.3 | 124.1 | |
| TP53 | Tumor protein p53 | 37.9 | 196.8 | |
| TP63 | Tumor protein p63 | 295.3 | 193.6 | |
| Growth factors and receptors, proteins of seboregulation | IGF1R | Insulin-like growth factor 1 receptor | 65.1 | 148.9 |
| SRD5A1 | Steroid 5α reductase, α polypeptide 1 | 89.5 | 77 | |
| CSF2 | Colony stimulating factor 2 | 210.5 | 56.4 |
ND, Non Detectable.
Figure 1Viability of reconstructed human epidermidis (RHE) exposed to .
Figure 2Relative expression of genes encoding for response to infection and inflammation proteins by reconstructed human epidermidis (RHE) exposed to . Results are expressed as percentages to control RHE exposed to bacteria pre-treated with Substance P reverse (dotted line = 100%). Each value represents the mean ± SEM of three independent experiments. Only genes showing significant variation of expression on the 64 (⋆p < 0.05; ⋆⋆p < 0.01; ⋆⋆⋆p < 0.001). Names of proteins are given in Table 1.
Figure 3Effect of Substance P (SP) and Substance P reverse (SPrev) (A), Substance P reverse (SA-SPrev) and Substance P treated . On each figures, dotted lines indicate the basal production of LL37 and HBD2 by HaCaT in the absence of treatment (control). Each value is the mean ± SEM of three independent experiments. (NS = non significant; ⋆p < 0.05; ⋆⋆p < 0.01; ⋆⋆⋆p < 0.001).
Figure 4Effect of the cathelicidin LL37 (1 μg/mL) and of β-defensin 2 (HBD2) (1 μg/mL) alone or in association on the cytotoxicity and biofilm formation activities of . Dotted lines indicate the basal cytotoxicity and biofilm formation activity of bacteria in the absence of treatment (control). Each value is the mean ± SEM of three independent experiments. (⋆p < 0.05; ⋆⋆p < 0.01).
Figure 5Effect of Substance P (SP) and Substance P reverse (SPrev) (10. The dotted line indicates the basal adhesion of bacteria (100%) in the absence of treatment (control). Each value is the mean ± SEM of three independent experiments (⋆⋆⋆p < 0.001).
Figure 6Bidimensional electrophoresis analysis of secreted Six spots were modified after exposure of the bacteria to SP. (B) Two proteins (1 and 6) were markedly decreased whereas the expression of four others was upregulated. Proteins corresponding to these spots are presented in Table 2. Results are representative of three independent experiments.
Proteins under- and over-expressed in the secretome of Substance P treated .
| 1 | Lipase | Predicted acetyltransferase and hydrolase with α/β hydrolase fold domain | 274 | 39 | 52 | 76557/8.38 | ||
| 2 | sec4 | Staphylococcal enterotoxin C2 | Staphylococcal/Streptococcal toxin 0B-fold and grasp domain | 156 | 18 | 56 | 32654/7.6 | |
| 3 | tig | Prolyl isomerase Protein export (chaperone) | 126 | 12 | 29 | 48893/5.35 | ||
| 4 | Lipase precursor | Esterase lipase domain | 135 | 14 | 37 | 44329/6.83 | ||
| 5 | citZ | Citrate synthase | Coenzyme A binding site, oxalacetate citrate binding site, catalytic triad | 205 | 18 | 39 | 42566/6.41 | |
| 6 | Hypothetical protein SAOUHSC_01802 | Oxalacetate citrate binding site, coenzyme A binding site, catalytic triad | 116 | 13 | 33 | 3237117.17 |
Figure 7Effect of Substance P reverse SPrev (Control) and Substance P (SP) (10. The biofilm formation activity of bacteria was observed after 2, 5, and 24 h. (A) Two dimensions (2D), reconstructed three-dimensions (3D) and ortho cuts (3D/z) images. Pictures are representative of three independent experiments. (B) Evolution of the thickness of the biofilm after 2 and 24 h incubation with SP. Each value represents the mean ± SEM of three independent experiments (⋆⋆p < 0.01; ⋆⋆⋆p < 0.001).
Figure 8SDS-PAGE analysis of . Line 1, ladder; Line 2, P. aeruginosa Ef-Tu (mass marker and positive control for western blot); Line 3, QSDA protein (negative control for western blot); Line 4, Substance P treated S. aureus membrane extracts (SA SP); Line 5, Substance P reverse treated S. aureus membrane extracts (SA SPrev); Line 6, Substance P treated S. epidermidis membrane extracts (SE SP), Line 7: Substance P reverse treated S. epidermidis membrane extracts (SE SPrev). Results are representative of three independent experiments.